International Journal of Health and Life Sciences

Published by: Kowsar

The Burden of Chronic Obstructive Pulmonary Disease and Its Risk Factors in the Iranian Population: Results from the Global Burden of Disease Study 2016

Neda Izadi 1 , *
Author Information
1 Ph.D Student, Student Research Committee, Department of Epidemiology, School of Public Health and Safety, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Article information
  • International Journal of Health and Life Sciences: July 2018, 4 (2); e80995
  • Published Online: October 1, 2018
  • Article Type: Brief Report
  • Received: June 18, 2018
  • Revised: August 3, 2018
  • Accepted: August 4, 2018
  • DOI: 10.5812/ijhls.80995

To Cite: Izadi N. The Burden of Chronic Obstructive Pulmonary Disease and Its Risk Factors in the Iranian Population: Results from the Global Burden of Disease Study 2016, Int J Health Life Sci. 2018 ; 4(2):e80995. doi: 10.5812/ijhls.80995.

Abstract
Copyright © 2018, International Journal of Health and Life Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
References
  • 1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2095-128. doi: 10.1016/S0140-6736(12)61728-0. [PubMed: 23245604].
  • 2. Institute for Health Metrics and Evaluation (IHME). GBD compare data visualization. Seattle WI, University of Washington; 2016. Available from: https://vizhub.healthdata.org/gbd-compare/.
  • 3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11). e442. doi: 10.1371/journal.pmed.0030442. [PubMed: 17132052]. [PubMed Central: PMC1664601].
  • 4. Nicolini A, Barbagelata E, Tagliabue E, Colombo D, Monacelli F, Braido F. Gender differences in chronic obstructive pulmonary diseases: A narrative review. Panminerva Med. 2018. doi: 10.23736/S0031-0808.18.03463-8. [PubMed: 29856178].
  • 5. Varmaghani M, Kebriaeezadeh A, Sharifi F, Sheidaei A, Rashidian A, Moradi-Lakeh M, et al. Death-specific rate due to asthma and chronic obstructive pulmonary disease in Iran. Clin Respir J. 2018;12(6):2075-83. doi: 10.1111/crj.12776. [PubMed: 29405628].
  • 6. GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: A systematic analysis for the global burden of disease study 2016. Lancet. 2017;390(10100):1260-344. doi: 10.1016/S0140-6736(17)32130-X. [PubMed: 28919118]. [PubMed Central: PMC5605707].
  • 7. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al. International variation in the prevalence of COPD (the BOLD study): A population-based prevalence study. Lancet. 2007;370(9589):741-50. doi: 10.1016/S0140-6736(07)61377-4. [PubMed: 17765523].
  • 8. de Marco R, Pesce G, Marcon A, Accordini S, Antonicelli L, Bugiani M, et al. The coexistence of asthma and chronic obstructive pulmonary disease (COPD): Prevalence and risk factors in young, middle-aged and elderly people from the general population. PLoS One. 2013;8(5). e62985. doi: 10.1371/journal.pone.0062985. [PubMed: 23675448]. [PubMed Central: PMC3651288].
  • 9. Winsemius HC, Jongman B, Veldkamp TIE, Hallegatte S, Bangalore M, Ward PJ. Disaster risk, climate change, and poverty: Assessing the global exposure of poor people to floods and droughts. Environ Dev Econ. 2018;23(3):328-48. doi: 10.1017/s1355770x17000444.
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments